Cargando…

Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer

BACKGROUND: High expression of human epidermal growth factor receptor type 2 (HER2) represents an aggressive subtype of breast cancer. Anti-HER2 treatment requires a theragnostic approach wherein sufficiently high receptor expression in biopsy material is mandatory. Heterogeneity and discordance of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alhuseinalkhudhur, Ali, Lubberink, Mark, Lindman, Henrik, Tolmachev, Vladimir, Frejd, Fredrik Y., Feldwisch, Joachim, Velikyan, Irina, Sörensen, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085990/ https://www.ncbi.nlm.nih.gov/pubmed/32201920 http://dx.doi.org/10.1186/s13550-020-0603-9

Ejemplares similares

Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT
por: Sörensen, Jens, et al.
Publicado: (2016)

Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT
por: Sandberg, Dan, et al.
Publicado: (2017)

Human Epidermal Growth Factor Receptor 2–Targeting [(68)Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer
por: Alhuseinalkhudhur, Ali, et al.
Publicado: (2023)

Radionuclide Therapy of HER2-Expressing Xenografts Using [(177)Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab
por: Liu, Yongsheng, et al.
Publicado: (2023)

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody(®) Molecules (177)Lu-ABY-271 and (177)Lu-ABY-027: Impact of DOTA Position on ABD Domain
por: Liu, Yongsheng, et al.
Publicado: (2021)

Preclinical Evaluation of (99m)Tc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake
por: Oroujeni, Maryam, et al.
Publicado: (2021)

Cellular Effects of HER3-Specific Affibody Molecules
por: Göstring, Lovisa, et al.
Publicado: (2012)

Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [(68)Ga]Ga-ABY-025 tracer
por: Jussing, Emma, et al.
Publicado: (2023)

Affibody molecules as engineered protein drugs
por: Frejd, Fredrik Y, et al.
Publicado: (2017)

Phase I clinical evaluation of (99m)Tc-labeled Affibody molecule for imaging HER2 expression in breast cancer
por: Bragina, Olga, et al.
Publicado: (2023)

Affibody Molecules as Targeting Vectors for PET Imaging
por: Tolmachev, Vladimir, et al.
Publicado: (2020)

Regularized reconstruction of digital time-of-flight (68)Ga-PSMA-11 PET/CT for the detection of recurrent disease in prostate cancer patients
por: Lindström, Elin, et al.
Publicado: (2019)

Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule (188)Re-ZHER2:41071
por: Liu, Yongsheng, et al.
Publicado: (2022)

In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct
por: Bass, Tarek Z., et al.
Publicado: (2017)

Affibody-mediated PET imaging of HER3 expression in malignant tumours
por: Rosestedt, Maria, et al.
Publicado: (2015)

Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis
por: Liu, Yongsheng, et al.
Publicado: (2022)

Imaging of CAIX-expressing xenografts in vivo using (99m)Tc-HEHEHE-ZCAIX:1 Affibody molecule
por: HONARVAR, HADIS, et al.
Publicado: (2014)

Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification
por: Malm, Magdalena, et al.
Publicado: (2013)

Correction: Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification
por: Malm, Magdalena, et al.
Publicado: (2013)

Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules
por: Rinne, Sara S., et al.
Publicado: (2020)

Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3
por: Oroujeni, Maryam, et al.
Publicado: (2022)

Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis
por: Klint, Susanne, et al.
Publicado: (2023)

In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor
por: Seijsing, Johan, et al.
Publicado: (2018)

HER3 PET Imaging: (68)Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to (89)Zr-Labeled Antibody and Antibody-Fragment-Based Tracers
por: Rinne, Sara S., et al.
Publicado: (2021)

Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules
por: Rinne, Sara S., et al.
Publicado: (2020)

Discovery, optimization and biodistribution of an Affibody molecule for imaging of CD69
por: Persson, Jonas, et al.
Publicado: (2021)

Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111
por: Rinne, Sara S., et al.
Publicado: (2019)

Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with (64)Cu Using NOTA and NODAGA
por: Tolmachev, Vladimir, et al.
Publicado: (2017)

Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity
por: Strand, Joanna, et al.
Publicado: (2015)

PET of HER2 Expression with a Novel (18)FAl Labeled Affibody
por: Xu, Yuping, et al.
Publicado: (2017)

Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution
por: Ding, Haozhong, et al.
Publicado: (2021)

Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts
por: Garousi, Javad, et al.
Publicado: (2019)

Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake
por: Rosestedt, Maria, et al.
Publicado: (2019)

Comparison of (68)Ga-PSMA-11 PET/CT with (11)C-acetate PET/CT in re-staging of prostate cancer relapse
por: Regula, Naresh, et al.
Publicado: (2020)

Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity
por: Fleetwood, Filippa, et al.
Publicado: (2014)

Molecular design of radiocopper-labelled Affibody molecules
por: Tolmachev, Vladimir, et al.
Publicado: (2018)

Fluorescent Affibody Molecule Administered In Vivo at a Microdose Level Labels EGFR Expressing Glioma Tumor Regions
por: de Souza, Ana Luiza Ribeiro, et al.
Publicado: (2016)

17AAG-induced internalisation of HER2-specific Affibody molecules
por: Göstring, Lovisa, et al.
Publicado: (2016)

Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer
por: Regula, Naresh, et al.
Publicado: (2022)

Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of (68)Ga-Labeled Tracers
por: Dahlsson Leitao, Charles, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_votmhb37rm19jpijou29n94eva